Biotech – the red-hot, high risk investment story

Biotech stocks have been booming over the last few years. Anyone who has invested will have made some very respectable profits. And it's a bull market that's set to continue for some time yet.
 
 
 
 
 
 


This could be the most important scientific breakthrough in our lifetimes

Science is only just getting to grips with the fact that 90% of our body is made up of bacteria – the microbiome. Bengt Saelensminde investigates.

I met a very interesting man last week

Stephen O’Hara’s biotech company Optibiotix aims to profit from the ‘human microbiome’. David Thornton explains what that is, and what it means for investors.

An exciting future for tech stocks

We live in a golden age of unprecedented technological change. Smart investors should get in early, says Jim Mellon.

Invest for a high-tech future

Technological change is everywhere, says Merryn Somerset Webb. Investors who don’t want to be left behind should read Jim Mellon’s new book.

How Maurice Saatchi is boosting the biotech industry

Biotech companies will soon be able to get new drugs to patients much faster. That’s good news for patients and investors, says Matthew Partridge.

This company could have made a breakthrough in cancer treatment

The best way to improve cancer treatment is early diagnosis. And this small-cap biotech company may have the key to doing just that, says Matthew Partridge.

A revolutionary new cancer treatment – and the blue-chip stock set to benefit

A new kind of cancer therapy could make a big difference to survival rates – and transform the fortunes of one big UK drugs company. Matthew Partridge explains.

How to invest in the battle against ageing

As life expectancy increases, pharmas and biotechs pioneering treatments for the diseases of old age will profit handsomely, says Matthew Partridge.

What we can learn from Neil Woodford’s new portfolio

The list of holdings in Neil Woodford’s new fund can teach investors a lot about how to construct a portfolio, says David Thornton.

How you could profit in the hunt for new antibiotics

The number of antibiotic-resistant bacteria is rising fast. But the search is on to find new drugs to combat them. Matthew Partridge explains how you could profit.

Showing page 1 of 7